安罗替尼联合程序性死亡蛋白-1抑制剂治疗晚期非小细胞肺癌患者的临床疗效

Clinical Efficacy of Anlotinib Combined with PD-1 Inhibitor in the Treatment of Advanced Non-Small Cell Lung Cancer

【目的】探讨安罗替尼联合程序性死亡蛋白-1(programmed death-1,PD-1)抑制剂联合治疗晚期非小细胞肺癌(NSCLC)患者的疗效。【方法】回顾性分析90例NSCLC患者的临床资料,按照治疗方法不同分为对照组(n=30,采用安罗替尼治疗)和观察组(n=60,接受安罗替尼联合PD-1抑制剂治疗)。比较两组患者的近期疗效、生存情况和药物安全性。【结果】观察组治疗后客观缓解率(ORR)为11.67%(7/60),疾病控制率(DCR)为60.00%(36/60),分别高于对照组的6.67%(2/30)和33.33%(10/30),且差异有统计学意义(P<0.05)。观察组患者的中位无进展生存期(PFS)为10个月,中位总生存期(OS)为13个月,高于对照组患者(中位PFS为7个月,中位OS为11个月),且差异有统计学意义(P<0.05)。两组各项不良反应发生率比较,差异均无统计学意义(P>0.05)。【结论】安罗替尼联合PD-1抑制剂治疗晚期NSCLC患者,可有效提高患者的近期疗效,同时延长患者的生存期。

【Objective】To investigate the efficacy of anlotinib combined with programmed death-1(PD-1)inhibitor in the treatment of patients with advanced non-small cell lung cancer(NSCLC).【Methods】A retrospective analysis was conducted on the clinical data of 90 NSCLC patients,who were divided into the control group(n=30,treated with anlotinib)and the observation group(n=60,treated with anlotinib combined with PD-1 inhibitor)based on different treatment methods.The short-term efficacy,survival,and drug safety of the two groups were compared.【Results】After treatment,the objective response rate(ORR)in the observation group was 11.67%(7/60),and the disease control rate(DCR)was 60.00%(36/60),which were higher than those in the control group[ORR:6.67%(2/30),DCR:33.33%(10/30)],with statistically significant differences(P<0.05).The median progression-free survival(PFS)in the observation group was 10 months,and the median overall survival(OS)was 13 months.Both PFS and OS in the observation group were longer than those in the control group(median PFS:7 months,median OS:11 months),with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).【Conclusion】The combination of anlotinib and PD-1 inhibitors in the treatment of advanced NSCLC can effectively improve the short-term efficacy and extend the survival time of patients.